Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phage Therapy for MRSE Periprosthetic Joint Infection
NCT06827041Phase 1Active, not recruiting
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Feb 2024
- Primary completion
- Feb 2025
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of bacteriophages in periprosthetic joint infection (PJI), sponsored by Ottawa Hospital Research Institute. Primary endpoints: Safety of phage therapy at 1 year and Efficacy of phage therapy (clinical response) at 1 year. Started Feb 2024; status: active, not recruiting.
02
Drugs
bacteriophages
03
Conditions
periprosthetic joint infection (PJI)
Beyond the preview
Go deeper on NCT06827041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06827041.